S&P 500 may face selling pressure as systematic funds reach full exposure
Investing.com -- Precision BioSciences, Inc. (NASDAQ:DTIL) stock surged 17% on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for its PBGENE-DMD treatment for Duchenne muscular dystrophy (DMD).
The designation highlights the significant unmet need for new therapeutic options for boys living with DMD, a rare genetic disorder that affects approximately 15,000 people in the United States. DMD primarily affects individuals under the age of 18 and is characterized by progressive muscle weakness.
Precision’s PBGENE-DMD program leverages the company’s proprietary ARCUS gene editing platform to excise exons 45-55 of the dystrophin gene. According to the company, this approach has the potential to benefit up to 60% of patients with DMD by permanently editing a patient’s DNA sequence to produce naturally-occurring, near full-length dystrophin protein.
"Our approach is designed to permanently edit a patient’s own DNA sequence, resulting in naturally-produced, near full-length dystrophin protein known to be functional in humans," said Cindy Atwell, Chief Development and Business Officer at Precision BioSciences.
With this designation, Precision may be eligible to receive a Priority Review Voucher upon FDA approval of PBGENE-DMD. This voucher can be used to receive FDA priority review for a different product or can be sold to another sponsor, potentially providing non-dilutive capital.
The clinical stage gene editing company is currently completing final IND-enabling toxicology studies and expects to generate initial clinical data in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.